SCHEMBL5129771

SCHEMBL5129771

Cc1cc2c(NCCc3ccc4c(c3)OCO4)nc(-c3cccnc3)nc2s1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.57
NPSR1 Q6W5P4 1/20 0.57
GBA1 P04062 10/20 0.50
PDE5A O76074 4/20 0.47
KDM4E B2RXH2 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
TSHR P16473 1/20 0.47
CYP2C19 P33261 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CLK4 Q9HAZ1 1/20 0.44
BCDIN3D Q7Z5W3 1/20 0.43
HPGD P15428 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7609676 0.95 MAPT (0.51) MAPTNPSR1GBA1PDE5AKDM4E
SCHEMBL5123309 0.91 MAPT (0.69) MAPTNPSR1GBA1PDE5AKDM4E
SCHEMBL5122898 0.90 MAPT (0.56) MAPTNPSR1GBA1PDE5AKDM4E
SCHEMBL5125323 0.90 MAPT (0.57) MAPTNPSR1GBA1PDE5AKDM4E
SCHEMBL5128167 0.89 PRKCI (0.50) MAPTNPSR1PDE5AKDM4ECYP1A2
SCHEMBL5123292 0.87 MAPT (0.55) MAPTNPSR1GBA1PDE5AKDM4E
SCHEMBL7514104 0.86 MAPT (0.54) MAPTNPSR1GBA1PDE5AKDM4E
SCHEMBL7519982 0.86 MAPT (0.52) MAPTNPSR1GBA1PDE5AKDM4E
SCHEMBL5122086 0.86 BCDIN3D (0.43) MAPTNPSR1PDE5AKDM4ECYP1A2
SCHEMBL5115699 0.86 MAPT (0.53) MAPTNPSR1GBA1PDE5AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045529-A1 Use Of Thienopyrimidines MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
EP-1685136-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 2006-08-02 EP disclosed
WO-2005047292-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 2005-05-26 WO disclosed
US-6432950-B1 ANTICANCER AGENTS; KILLING CANCER CELLS CELL PATHWAYS 2002-08-13 US disclosed
US-6133271-A Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives CELL PATHWAYS, INC. (US) 2000-10-17 US disclosed
US-6110920-A TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-08-29 US disclosed
EP-0920431-A1 THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 1999-06-09 EP disclosed
WO-1998006722-A1 THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 1998-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045529-A1 Use Of Thienopyrimidines TIE1, DPYD, TK2 MAPT 2997/4885NPSR1 3053/4885GBA1 4788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.